17:28 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

BioCanCell reports Phase I/IIa data for BC-819 in bladder cancer

BioCanCell Ltd. (Tel Aviv:BICL) reported final data from a Phase I/IIa trial in 38 patients with resected, early stage non-muscle invasive bladder cancer (NMIBC) showing that BC-819 plus bacillus Calmette-Guérin (BCG) led to a 24-month...
22:49 , Jan 5, 2018 |  BC Week In Review  |  Company News

BioCanCell shareholders turn down offer to go private

BioCanCell Therapeutics Inc. (Tel Aviv:BICL) said its shareholders did not approve a full tender offer led by its largest shareholder Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) to take BioCanCell private. According to BioCanCell, the offering...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

BC-819: Pilot trial data

A pilot trial in 38 intermediate- and high-risk bladder cancer patients showed that an alternating treatment regimen with BC-819 followed by bacillus Calmette-Guerin (BCG) once or twice weekly was safe with no severe treatment-related adverse...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

BC-819 regulatory update

FDA granted Fast Track designation to BioCancell’s BC-819 to treat bladder cancer. Next half, the company plans to start 2 Phase III trials of the plasmid encoding diphtheria toxin to treat non-muscle invasive bladder cancer....
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

BC-819: Additional Phase IIb data

Data from the second treatment cohort in an open-label, U.S. and Israeli Phase IIb trial in 39 patients with SBC that had failed prior treatment showed that 6 weekly intravesical instillations of 20 mg BC-819...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

BC-819: Phase IIb started

BioCancell began an open-label, international Phase IIb trial to compare 8 and 12 mg intratumoral BC-819 plus 1,000 mg/m 2 IV gemcitabine vs. gemcitabine alone in about 100 patients with locally advanced, unresectable pancreatic cancer....
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

BC-819: Phase I/IIa data

A U.S. and Israeli Phase I/IIa trial in 9 patients showed that twice-weekly 4 and 8 mg BC-819 for 2 weeks met the primary safety endpoint with no drug-related side effects or complaints about pain...
07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

BC-819: Interim Phase IIb data

Interim data from 18 patients in an ongoing U.S. and Israeli Phase IIb trial showed that 20 mg BC-819 produced a complete response rate of 22%, defined as achieving both non-recurrence and tumor ablation. Rates...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Clinical News

BC-819 regulatory update

FDA granted Orphan Drug designation for BioCancell's BC-819 to treat ovarian cancer. The plasmid encoding diphtheria toxin is in Phase I/IIa testing for the indication. BioCancell Therapeutics Inc. (Tel Aviv:BICL), Jerusalem, Israel   Product: BC-819...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

BC-819: Compassionate use program data

Data from an Israeli compassionate use study in 1 patient with TCC showed that there were no new growths in the renal pelvis 4 months after the completion of treatment. The patient, who had previously...